PURE Bioscience (OTCMKTS:PURE) released its earnings results on Thursday. The company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01, reports. PURE Bioscience had a negative return on equity of 125.22% and a negative net margin of 276.96%.
PURE Bioscience (OTCMKTS PURE) traded up 2.78% during mid-day trading on Thursday, reaching $1.11. PURE Bioscience has a 12 month low of $0.75 and a 12 month high of $1.36. The firm’s market cap is $69.60 million. The firm’s 50 day moving average price is $1.03 and its 200 day moving average price is $1.09.
Separately, ValuEngine raised PURE Bioscience from a “sell” rating to a “hold” rating in a research note on Friday, September 1st.
WARNING: “PURE Bioscience (PURE) Issues Earnings Results, Beats Estimates By $0.01 EPS” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/pure-bioscience-pure-issues-earnings-results-beats-estimates-by-0-01-eps.html.
PURE Bioscience Company Profile
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.